Display options
Share it on

Cureus. 2019 Apr 23;11(4):e4526. doi: 10.7759/cureus.4526.

Disopyramide for Hypertrophic Cardiomyopathy.

Cureus

Alejandro Sanchez-Nadales, Andrea Anampa-Guzmán, Amir Khan

Affiliations

  1. Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, USA.
  2. Internal Medicine, Main National University of San Marcos, Lima, PER.

PMID: 31263635 PMCID: PMC6592455 DOI: 10.7759/cureus.4526

Abstract

Hypertrophic cardiomyopathy (HCM) is a cardiac disease characterized by hypertrophy of a nondilated left ventricle without any other cardiac or systemic disease that could account for observed hypertrophy. We present a female patient with the diagnosis of obstructive HCM, which is rare because sudden death is frequently the first clinical presentation. Her symptoms were resistant to medical treatment and the patient did not want invasive procedures. Disopyramide was added, and it improved her symptoms. Disopyramide is a safe and effective medication that reduces symptoms and delays the need for invasive therapy. Disopyramide was added to the treatment of the patient and it improved her symptoms.

Keywords: cardiomyopathy; hypertrophic; myosin

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. N Engl J Med. 2003 Apr 24;348(17):1647-55 - PubMed
  2. J Am Coll Cardiol. 2005 Apr 19;45(8):1251-8 - PubMed
  3. Circulation. 2011 Dec 13;124(24):e783-831 - PubMed
  4. Lancet. 2013 Jan 19;381(9862):242-55 - PubMed
  5. J Cardiol. 2014 Jul;64(1):1-10 - PubMed
  6. Eur Heart J. 2014 Oct 14;35(39):2733-79 - PubMed
  7. Pharmacotherapy. 2015 Dec;35(12):1164-72 - PubMed
  8. J Am Coll Cardiol. 2016 Dec 27;68(25):2871-2886 - PubMed
  9. JAMA Intern Med. 2017 Apr 1;177(4):573-574 - PubMed
  10. J Am Heart Assoc. 2017 May 26;6(6):null - PubMed
  11. Cardiol Young. 2018 Apr;28(4):530-535 - PubMed

Publication Types